Global Gene Therapy for CNS Disorders Market 2019-2023
SKU ID : TNV-14098788 | Publishing Date : 28-Mar-2019 | No. of pages : 119
Detailed TOC of Global Gene Therapy for CNS Disorders Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY INDICATION
• Market segmentation by indication
• Comparison by indication
• SMA - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by indication
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen
• bluebird bio, Inc.
• Novartis AG
• Pfizer Inc.
• Voyager Therapeutics
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global gene therapy for CNS disorders market pipeline: Overview
Exhibit 18: Global gene therapy for CNS disorders market pipeline: Snapshot
Exhibit 19: Indication - Market share 2018-2023 (%)
Exhibit 20: Comparison by indication
Exhibit 21: SMA - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: SMA - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by indication
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Biogen - Vendor overview
Exhibit 50: Biogen - Business segments
Exhibit 51: Biogen - Organizational developments
Exhibit 52: Biogen - Geographic focus
Exhibit 53: Biogen - Key offerings
Exhibit 54: Biogen - Key customers
Exhibit 55: bluebird bio, Inc. - Vendor overview
Exhibit 56: bluebird bio, Inc. - Product segments
Exhibit 57: bluebird bio, Inc. - Organizational developments
Exhibit 58: bluebird bio, Inc. - Key offerings
Exhibit 59: bluebird bio, Inc. - Key customers
Exhibit 60: Novartis AG - Vendor overview
Exhibit 61: Novartis AG - Business segments
Exhibit 62: Novartis AG - Organizational developments
Exhibit 63: Novartis AG - Geographic focus
Exhibit 64: Novartis AG - Segment focus
Exhibit 65: Novartis AG - Key offerings
Exhibit 66: Novartis AG - Key customers
Exhibit 67: Pfizer Inc. - Vendor overview
Exhibit 68: Pfizer Inc. - Business segments
Exhibit 69: Pfizer Inc. - Organizational developments
Exhibit 70: Pfizer Inc. - Geographic focus
Exhibit 71: Pfizer Inc. - Segment focus
Exhibit 72: Pfizer Inc. - Key offerings
Exhibit 73: Pfizer Inc. - Key customers
Exhibit 74: Voyager Therapeutics - Vendor overview
Exhibit 75: Voyager Therapeutics - Business segments
Exhibit 76: Voyager Therapeutics - Organizational developments
Exhibit 77: Voyager Therapeutics - Key offerings
Exhibit 78: Voyager Therapeutics - Key customers
Exhibit 79: Validation techniques employed for market sizing
Keyplayers in Global Gene Therapy for CNS Disorders Market 2019-2023
Biogenbluebird bio, Inc.
Novartis AG
Pfizer Inc.
Voyager Therapeutics